Rama Rao Malla*

Cancer Biology Research Laboratory, Department of Biochemistry and Bioinformatics, GIS, GITAM (Deemed to be University), Visakhapatnam, India

*Corresponding Author: Rama Rao Malla, Cancer Biology Research Laboratory, Department of Biochemistry and Bioinformatics, GIS, GITAM (Deemed to be University), Visakhapatnam, India.

Received: July 17, 2018; Published: July 20, 2018

Citation: Rama Rao Malla. “CD151 - A Typical Therapeutic and Diagnostic Marker of Breast Cancers". Acta Scientific Cancer Biology 2.6 (2018).

  Triple negative breast cancer (TNBC) is highly aggressive subtype, commonly diagnosed in younger women (< 50 years), with limited treatment options. TNBC patients have poor survival and increased risk of visceral and central nervous system metastases. Diagnosis of TNBC at early stage can increase the survival rate, avoid metastasis and requires less expensive treatment. However, early detection is one of the major challenges in the struggle against this disease. These facts underscore the pressing need of novel biomarkers, strategies, and technologies.

Copyright: © 2018 Rama Rao Malla. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.